Nivolumab plus Ipilimumab in Advanced Melanoma
Nivolumab plus Ipilimumab in Advanced Melanoma
Publisher:
New England Journal of Medicine
Date published:
2013
Record type:
Journal Title:
The New England Journal of Medicine
Source:
The New England Journal of Medicine, Vol. 369, No. 2, July 11, 2013, pp. 122-133
Subject:
Abstract:
A combination of antibodies to two T-cell checkpoints, CTLA-4 and PD-1, produced tumor responses in 40% of patients in a phase 1 study. Elevated lipase levels indicated dose-limiting toxicity.
Language:
Catagory URL:
CITATION: Wolchock, J.D. [etal]. Nivolumab plus Ipilimumab in Advanced Melanoma . : New England Journal of Medicine , 2013. The New England Journal of Medicine, Vol. 369, No. 2, July 11, 2013, pp. 122-133 - Available at: https://library.au.int/nivolumab-plus-ipilimumab-advanced-melanoma-4